| Serum sample |
Luminex- (Single Donor/ ID) Ab specificities |
PRA (%) |
AMS-ELISA-CM |
| Class I |
Class II |
| 08/2012 & |
Class I: anti-A9 (23,24), -B7 -B27, -B40 (60,61), -B47, -B81 |
54% |
n.d. |
n.d. |
| Class II: neg. |
0% |
|
|
| 07/2013 # |
Class I: anti-A9 (23,24), -B7 -B27, -B40 (60,61), -B47, -B81 |
60% |
pos. (1:6) |
neg. |
| Class II: neg. |
0% |
|
|
| 08/2013 § |
Class I: anti-A9 (23,24) , -B7 -B27, -B40 (60,61), -B47, -B81 |
58% |
pos. (1:6) |
neg. |
| Class II: neg. |
0% |
|
|
| n.d.: not done; neg.: negative; pos.: positive; &: antibody specification as prerequisite for entering the waiting list; #: antibody analyses at the date of the rejection episode; §: antibody analyses after three apheresis cycles; bold lettering: donor-specific antibodies as detected by virtual (Luminex) or de facto (AMS-ELISA) cross-matching at the highest dilution (parentheses). |
|
